Mihalcioiu, Catalin

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 5,519

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

Mahmood, N., Mihalcioiu, C., & Rabbani, S. A. (2018) · Frontiers in Oncology

Protease and Inhibitor MechanismsBlood Coagulation and Thrombosis Mechanisms

Cited by 478

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 437

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 352

A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability

Sirois, I., Aguilar-Mahecha, A., Lafleur, J., Fowler, E., Vu, V., Scriver, M., Buchanan, M., Chabot, C., Ramanathan, A., Balachandran, B., et al. (2019) · Molecular Cancer Research

Cancer, Lipids, and MetabolismBreast Cancer Treatment Studies

Cited by 110

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors

Tonneau, M., Nolin-Lapalme, A., Kazandjian, S., Auclin, E., Panasci, J., Benlaifaoui, M., Ponce, M., Al-Saleh, A., Belkaid, W., Naimi, S., et al. (2022) · OncoImmunology

Cancer Immunotherapy and BiomarkersHelicobacter pylori-related gastroenterology studies

Cited by 34